Spring til hovednavigation Spring til søgning Spring til hovedindhold

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

  • Mikkel Østergaard*
  • , Ronald F van Vollenhoven
  • , Anna Rudin
  • , Merete Lund Hetland
  • , Marte Schrumpf Heiberg
  • , Dan C Nordström
  • , Michael T Nurmohamed
  • , Bjorn Gudbjornsson
  • , Lykke Midtbøll Ørnbjerg
  • , Pernille Bøyesen
  • , Kristina Lend
  • , Kim Hørslev-Petersen
  • , Till Uhlig
  • , Tuulikki Sokka
  • , Gerdur Grondal
  • , Simon Krabbe
  • , Joakim Lindqvist
  • , Inger Gjertsson
  • , Daniel Glinatsi
  • , Meliha Crnkic Kapetanovic
    • Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljoså, Eli Brodin, Hanne Lindegaard, Annika Söderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Søren Andreas Just, David J Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A Haavardsholm, Jon Lampa, NORD-STAR study group
*Corresponding author af dette arbejde
53 Citationer (Scopus)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial'. Sammen danner de et unikt fingeraftryk.
Sorter

Keyphrases

Medicine and Dentistry